ID   CH-01
AC   CVCL_C7NF
SY   Clone 3; anti-CHRNB2 mAb-3
DR   Wikidata; Q117704239
RX   Patent=US12098205;
RX   PubMed=34331011;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE BP-02857.
CC   Monoclonal antibody isotype: Not specified.
CC   Monoclonal antibody target: UniProtKB; P17787; Human CHRNB2.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3412 ! P3X63Ag8U.1
CA   Hybridoma
DT   Created: 21-03-23; Last updated: 10-04-25; Version: 4
//
RX   Patent=US12098205;
RA   Kanda M.;
RT   "Therapeutic agent targeted to receptor protein, test agent, antibody
RT   that binds to receptor protein, and screening method for molecularly
RT   targeted drugs.";
RL   Patent number US12098205, 24-Sep-2024.
//
RX   PubMed=34331011; DOI=10.1038/s41388-021-01945-9;
RA   Kanda M., Shimizu D., Nakamura S., Sawaki K., Umeda S., Miwa T.,
RA   Tanaka H., Inokawa Y., Hattori N., Hayashi M., Tanaka C., Nakayama G.,
RA   Iguchi Y., Katsuno M., Kodera Y.;
RT   "Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody
RT   attenuates the aggressiveness of gastric cancer cells.";
RL   Oncogene 40:5495-5504(2021).
//